Fresenius SE & Co. KGaA stock (DE0005785604): UBS keeps buy stance, target at EUR 54

Fresenius shares stayed in focus on Xetra after UBS reiterated its Buy view and kept a EUR 54 target, while the stock also drew attention from a reported CEO share purchase.

Fresenius SE & Co. KGaA remained in focus on Germany's Xetra market on 06/03/2026 after UBS kept a Buy rating on the stock and left its target price at EUR 54, according to MarketScreener's report on the note. The stock last closed at EUR 36.45, and the gap to the cited target remains a central reference point for investors tracking the DAX-listed healthcare group.

A separate ad-hoc-news.de report said chief executive Michael Sen had disclosed a share purchase, adding a company-specific ownership signal to the day's news flow on the German listing venue. Fresenius is headquartered in Bad Homburg, Germany, and trades in EUR on Xetra under the ISIN DE0005785604, which keeps the home-country angle firmly centered on the German market.

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Fresenius
• Sector/industry: Healthcare services and medical products
• Headquarters/country: Bad Homburg, Germany
• Core markets: Europe, North America, and selected international markets
• Key revenue drivers: Hospital operations, medical products, clinical nutrition, and related healthcare services
• Home exchange/listing venue: Xetra (FRE)
• Trading currency: EUR

Fresenius SE & Co. KGaA: core business model

Fresenius builds revenue around healthcare services and medical products, with hospital operations and medical technology at the center of its current structure. The company also relies on clinical nutrition, infusion therapies, and related product lines to diversify demand across care settings.

Recent corporate actions

The latest company-specific ownership signal came from the disclosed CEO share purchase reported by ad-hoc-news.de, which added to the stock's immediate news flow alongside the broker note. No completed delisting, take-private, or liquidation evidence was identified in the available dated sources, so the shares remain treated as actively listed in Germany.

Fresenius SE & Co. KGaA in peer comparison

Within German healthcare and medtech coverage, Fresenius is often viewed against Fresenius Medical Care and larger European healthcare names such as Siemens Healthineers and Sartorius, but the operating mix is different from each of them. MarketScreener's cited note puts the stock at EUR 36.45 versus an average target price of EUR 54.79 across coverage, underlining that valuation debates remain active on the German market.

That comparison matters because Fresenius combines hospital exposure with medical products, while peers tend to lean more heavily toward dialysis, imaging, laboratory tools, or consumables. For German investors, the main reference point remains the Xetra line in EUR rather than a foreign listing or ADR structure.

Conclusion

The day's main catalyst is the UBS view with its unchanged EUR 54 target, reinforced by the separate CEO purchase disclosure and the stock's current Xetra price. In peer terms, the latest market discussion keeps centering on where Fresenius fits inside the German healthcare complex and how much upside or downside the cited target still implies.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.